Agilent Technologies vs Teva Pharmaceutical Industries

Agilent Technologies (A), health care, and Teva Pharmaceutical Industries (TEVA), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Teva Pharmaceutical Industries is worth $49.8B on the stock market and Agilent Technologies $48.6B: Teva Pharmaceutical Industries is valued at 2% more. Agilent Technologies trades at 34.0 times earnings and Teva Pharmaceutical Industries at 99.2; operating margins in their latest fiscal years were 21.3% and 12.5%. Over the past year Agilent Technologies's share price has moved +20.2% and Teva Pharmaceutical Industries's +71.4%.

Key facts

Agilent Technologies market value
$48.6B
Teva Pharmaceutical Industries market value
$49.8B
Agilent Technologies P/E
34.0
Teva Pharmaceutical Industries P/E
99.2
Agilent Technologies revenue
$6.9BFY to 2025-10-31
Teva Pharmaceutical Industries revenue
$17.3BFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Agilent Technologies vs Teva Pharmaceutical Industries: every measure side by side
Measure Agilent Technologies Teva Pharmaceutical Industries
SectorHealth CareHealth Care
Country United States Israel
Fiscal year ends2025-10-312025-12-31
Size
Market cap$48.6Blower$49.8Bhigher
Revenue$6.9Blower$17.3Bhigher
Earnings$1.3Blower$1.4Bhigher
Employees18,200lower31,173higher
Total assets$12.7Blower$40.7Bhigher
Valuation
P/E34.0lower99.2higher
P/S7.0higher2.9lower
P/B6.6—
Dividend yield0.59%—
Profitability
Operating margin21.3%higher12.5%lower
Balance sheet
Net assets$6.7Blower$7.9Bhigher
Total liabilities$6Blower$32.8Bhigher
Total debt$3.4B—
Cash on hand$1.8Blower$3.6Bhigher
Price change
Today-0.38%lower+0.19%higher
1 year+20.2%lower+71.4%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (1)

Agilent Technologies only (3)

Teva Pharmaceutical Industries only (6)

Percentages are each holding's share of that investor's reported portfolio (under "Both": Agilent Technologies / Teva Pharmaceutical Industries). Who owns A · Who owns TEVA

Further comparisons

Learn

Questions and answers

Which is bigger, Agilent Technologies or Teva Pharmaceutical Industries?

By market value, Teva Pharmaceutical Industries is the larger: $49.8B against $48.6B for Agilent Technologies. By revenue in its latest fiscal year, Teva Pharmaceutical Industries is the larger: $17.3B against $6.9B for Agilent Technologies.

Which has the higher P/E ratio?

Teva Pharmaceutical Industries: 99.2, against 34.0 for Agilent Technologies. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Agilent Technologies: 21.3%, against 12.5% for Teva Pharmaceutical Industries. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both Agilent Technologies and Teva Pharmaceutical Industries?

In their latest 13F filings, Larry Robbins holds both.

Cite this page

Funkfolio, “Agilent Technologies vs Teva Pharmaceutical Industries”, data as of 17 November 2026. https://funkfolio.com/compare/a-vs-teva

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.